RxDoctor Payments Data

Kuimil Mohan, MD

Neurology · Indianapolis, INNPI 1407850068

Payments from drug & device makers

$22,518in general payments, 2019–2025

Across 1,378 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Novartis$2K
  • Jazz Pharmaceuticals Inc.$1K
  • Harmony Biosciences LLC$1K
  • EMD Serono, Inc.$823
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$22,30399%
  • Education$2151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)201$2,763
UCB, Inc.169$2,002
Novartis118$1,749
Jazz Pharmaceuticals Inc.51$1,333
Harmony Biosciences LLC62$1,156
EMD Serono, Inc.50$823
Eisai Inc.37$779
Amgen(2 entities)39$718
Supernus Pharmaceuticals, Inc.68$683
Biogen38$662
Sanofi30$649
Sunovion Pharmaceuticals Inc.39$543
Neurocrine Biosciences, Inc.27$527
Teva Pharmaceuticals USA, Inc.47$472
AstraZeneca(2 entities)23$468
Bristol Myers Squibb26$456
Lilly USA, LLC31$445
Alnylam Pharmaceuticals Inc.18$418
Argenx US, Inc.20$417
Livanova USA, Inc.22$395
Vanda Pharmaceuticals Inc.7$351
Arbor Pharmaceuticals, Inc.16$294
Genentech USA, Inc.20$293
MDD US Operations, LLC14$258
Pfizer15$227
Lundbeck LLC9$209
Catalyst Pharmaceuticals, Inc.7$189
Amneal Pharmaceuticals LLC10$184
TG Therapeutics, Inc.6$167
Sumitomo Pharma America, Inc.9$164
Upsher-smith Laboratories LLC8$163
Johnson & Johnson16$161
Takeda Pharmaceuticals U.S.A., Inc.5$140
Axsome Therapeutics, Inc.7$135
Neurelis, Inc.5$123
Banner Life Sciences, LLC5$116
Adamas Pharmaceuticals, Inc.7$115
Avadel CNS Pharmaceuticals, LLC5$109
Tanabe Pharma America, Inc.5$108
Avanir Pharmaceuticals, Inc.7$97
Otsuka America Pharmaceutical, Inc.5$94
Inspire Medical Systems, Inc.4$82
Almatica Pharma LLC4$79
Greenwich Biosciences, Inc.4$74
Promius Pharma LLC4$69
Acorda Therapeutics, Inc3$67
SK Life Science, Inc.3$66
CSL Behring3$63
Acadia Pharmaceuticals Inc4$62
Assertio Therapeutics, Inc.4$53
Biohaven Pharmaceutical Holding Company Ltd.3$52
Scilex Pharmaceuticals Inc.3$51
Bausch Health US, LLC2$50
Sanofi-aventis U.S. LLC2$47
Biohaven Pharmaceuticals, Inc.3$45
Boston Scientific3$44
Azurity Pharmaceuticals, Inc.2$39
Currax Pharmaceuticals LLC3$39
Mallinckrodt Hospital Products Inc.1$34
Microtransponder, Inc.1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,518 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$177,990
Medicare patients
697
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate25$525,767
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$221,465
TecfideraDimethyl Fumarate11$103,893
Avonex Pen (4 Pack)Interferon Beta-1a12$99,190
Nurtec OdtRimegepant Sulfate41$61,717
Aimovig AutoinjectorErenumab-Aooe45$35,611
Emgality PenGalcanezumab-Gnlm46$31,547
HorizantGabapentin Enacarbil23$24,574
UbrelvyUbrogepant16$21,358
BriviactBrivaracetam12$18,004
AptiomEslicarbazepine Acetate12$14,338
Armodafinil19$7,874
Levetiracetam ErLevetiracetam51$4,861
Lacosamide20$4,188
Levetiracetam74$3,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$662$103,89311 claims
PfizerNurtec Odt$227$61,71741 claims
Arbor Pharmaceuticals, Inc.Horizant$294$24,57423 claims
AbbVieUbrelvy$2,763$21,35816 claims
UCB, Inc.Briviact$2,002$18,00412 claims
Sunovion Pharmaceuticals Inc.Aptiom$543$14,33812 claims
Upsher-smith Laboratories LLCTopiramate$163$35142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →